IL2 and neuroblastoma: Flaadt et al. retrospectively reviewed the data of 13 patients with HR-NB who had a central nervous system (CNS) relapse and who received multimodal therapy with consolidating haplo-SCT followed by DB plus subcutaneous interleukin-2 (scIL-2).